Trial NCT05614453

View at ClinicalTrials.gov 
Org. Study IDs: ANZGOG 2002/2021

Last trial update was posted on 2023-06-29

MeSH Interventions

Tislelizumab

MeSH Conditions

Uterine Cervical Neoplasms

Other Conditions

Metastatic Cervical Cancer

Stopping Reasons

BeiGene has withdrawn their support owing to sitravatinib supply concerns. Mirati is ceasing further development of sitravatinib owing to the negative results of the SAPPHIRE trial which used sitravatinib in 2nd line met NSCLC setting.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID